DEFA14A: Monogram Technologies to be Acquired by Zimmer Biomet

Monogram Technologies Inc. announced it will be acquired by Zimmer Biomet Holdings, Inc. for $4.04 cash per share plus a Contingent Value Right.

Summary

• Monogram Technologies Inc. will be acquired by Zimmer Biomet Holdings, Inc. as previously announced on July 14, 2025.
• Each outstanding common share of Monogram will be converted into the right to receive $4.04 in cash and one Contingent Value Right (CVR).
• CVRs are contractual rights to additional payments contingent upon achieving specific commercial, regulatory, or revenue-based milestones.
• CVRs are not tradeable or transferable (except under very limited conditions), do not have voting or dividend rights, and do not represent equity or ownership interest.
• Potential CVR payments range from $1.04 up to $3.43 per CVR, but there is no guarantee these milestones will be met or payments will occur.
• The merger is expected to close in the second half of 2025, pending regulatory and Monogram stockholder approval.
• Monogram shares will continue trading on Nasdaq until the merger closes, after which Monogram will be delisted and become a wholly-owned subsidiary of Zimmer Biomet.
• Stockholders holding shares in book-entry form/DRS will receive instructions for exchange; those holding in street name should contact their brokerage firm.
• A proxy statement with voting instructions will be mailed to stockholders in approximately 1-2 months.

Sentiment

Score: 7

Explanation: The sentiment is generally positive as it announces a definitive acquisition with a fixed cash component and potential upside through CVRs, providing a clear path for shareholder value realization. However, the contingent nature of CVRs and the inherent risks of merger completion introduce some uncertainty.

Positives

• Provides a definitive cash value of $4.04 per share for Monogram stockholders.
• Offers potential additional upside through Contingent Value Rights (CVRs) ranging from $1.04 to $3.43 per CVR.
• The acquisition provides a clear exit strategy for Monogram shareholders and integrates the company into a larger entity, Zimmer Biomet.

Negatives

• Contingent Value Right (CVR) payments are not guaranteed and are entirely dependent on the achievement of specific milestones.
• CVRs are not tradeable or transferable, limiting liquidity for the contingent portion of the consideration.
• Monogram will be delisted from Nasdaq and cease to exist as an independent publicly traded company after the merger closes.

Risks

• Risks related to the satisfaction of closing conditions, including failure to obtain necessary regulatory approvals or Monogram stockholder approval.
• Possibility of competing offers or acquisition proposals for Monogram.
• Occurrence of any event, change, or circumstances that could lead to the termination of the definitive transaction agreement, potentially requiring Monogram to pay a termination fee.
• Inability to realize the anticipated benefits of the proposed transaction, or realization not within the expected timeframe.
• Risk that the businesses will not be integrated successfully.
• Risks relating to changing demand for Zimmer Biomet's and Monogram's existing products.
• Risks relating to the achievement, in part or at all, of the revenue and other milestones necessary for any CVR payments.
• Disruption from the proposed transaction making it more difficult to maintain business and operational relationships.
• Monogram's ability to attract, motivate, or retain key executives, employees, and other associates.
• Risks related to the proposed transaction diverting management's attention from ongoing business operations.
• Negative effects of the announcement or consummation of the proposed transaction on the market price of common stock and operating results.
• Significant transaction costs and unknown liabilities.
• Risk of litigation, including stockholder litigation, and/or regulatory actions related to the proposed transaction.

Future Outlook

The proposed acquisition is expected to close in the second half of 2025, subject to regulatory and stockholder approvals. Future payments from Contingent Value Rights (CVRs) are entirely contingent on the achievement of specific commercial, regulatory, or revenue-based milestones, with no guarantee of occurrence.

Management Comments

• Benjamin Sexson, Chief Executive Officer, signed the Form 8-K on behalf of Monogram Technologies Inc.

Industry Context

This acquisition represents a consolidation event within the medical technology and orthopedics sector, where larger players like Zimmer Biomet seek to expand their portfolios or capabilities by acquiring specialized companies like Monogram Technologies. Such mergers are common in mature industries looking for growth through strategic integration.

Comparison to Industry Standards

• The filing does not provide specific financial or operational results for Monogram Technologies Inc. that would allow for a direct comparison to global benchmarks or specific comparable companies/projects within the medical device industry. The focus is solely on the terms and process of the proposed acquisition.

Legal Proceedings

• Risk of litigation, including stockholder litigation, and/or regulatory actions related to the proposed transaction.

Stakeholder Impact

• Shareholders: Will receive $4.04 cash per share plus one Contingent Value Right (CVR) for potential future payments, and Monogram shares will be delisted.
• Employees: Subject to risks related to business integration and the ability to attract, motivate, or retain key executives and other associates.
• Customers, Vendors, Service Providers: Potential disruption from the proposed transaction making it more difficult to maintain business and operational relationships.

Next Steps

• Monogram will file preliminary and definitive proxy statements with the SEC.
• The definitive proxy statement will be mailed to Monogram's stockholders with voting instructions.
• Monogram stockholders will vote on the proposed transaction.
• Obtain necessary regulatory approvals for the merger.
• Consummation of the proposed transaction, expected in the second half of 2025.
• Following closing, Monogram will be delisted from Nasdaq and become a wholly-owned subsidiary of Zimmer Biomet.

Key Dates

Recommendation

For existing shareholders, holding the stock until the merger closes allows them to receive the announced cash consideration of $4.04 per share and the Contingent Value Right (CVR). Selling before closing would mean forfeiting the right to the merger consideration. For new investors, buying now would be an arbitrage play on the spread between the current market price and the merger consideration, but the CVR's contingent nature adds uncertainty to the total value.

Keywords

Monogram Technologies, Zimmer Biomet, acquisition, merger, Contingent Value Right, CVR, medical devices, orthopedics, healthcare technology, corporate action